The company currently has 31.2 million shares outstanding and the stock repurchases will be funded through available cash.
Shares of the Waltham, Mass.-based therapeutics developer closed Tuesday at $4.75.
Greg Saulnier gs/pc
COPYRIGHT
Copyright Thomson Financial News Limited 2007. All rights reserved. The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.
MMMM
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index